|
PDUFA IV Successes Touted by FDA As Reauthorization Process Continues
As Congress gears up to tackle reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA continues to tout its performance goal record as the current five-year program draws to a close.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives